Immune treatment in COVID-19.

Area of Science:

• Immunology
• Virology
• Infectious Diseases

Background:

• Current antiviral strategies primarily involve convalescent plasma and monoclonal antibodies (mAbs).
• Meta-analyses indicate no significant clinical benefit of convalescent plasma over standard care for viral infections.
• Monoclonal antibodies (mAbs) are engineered proteins designed to neutralize viruses like SARS-CoV-2 by preventing cell entry.

Purpose of the Study:

• To review the efficacy of current immune treatments against viral replication.
• To assess the impact of SARS-CoV-2 variants on the effectiveness of monoclonal antibodies.
• To identify knowledge gaps and areas for future research in antiviral therapies.

Main Methods:

• Systematic review and meta-analysis of clinical trials.
• Analysis of in vitro studies assessing antibody neutralization.
• Review of clinical data on patient outcomes with different therapeutic interventions.

Main Results:

• Convalescent plasma demonstrated no clinical benefit compared to standard care.
• Several mAbs, including casirivimab-imdevimab, bamlanivimab-etesevimab, and sotrovimab, initially showed efficacy in reducing viral load and disease progression.
• The emergence of the Omicron variant led to a loss of neutralizing activity for casirivimab-imdevimab and bamlanivimab-etesevimab, while sotrovimab retained activity.

Conclusions:

• Monoclonal antibodies are a promising therapeutic avenue, but their effectiveness is threatened by evolving viral variants.
• Ongoing monitoring of variant evolution and its impact on antibody efficacy is crucial.
• Further research is needed to address patient selection, optimal dosing, timing, and serological status for effective treatment strategies.